Point Biopharma
- Company typePublic
- Founded2017
- HeadquartersIndianapolis, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Point Biopharma firmographics
Firmographics- Name
- Point Biopharma
- Legal name
- Point Biopharma Global Inc.
- Website
- https://pointbiopharma.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Point Biopharma industry classification
Industry- Product category
- Radiopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
- akta.pro secondary industries
- Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE)
Keywords
Where Point Biopharma is headquartered
LocationHeadquarters
- HQ city
- Indianapolis
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Point Biopharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Supply Chain, Infrastructure
Revenue model
- Radiopharmaceutical Development: Point Biopharma was a clinical-stage radiopharmaceutical company developing targeted radioligand therapies for cancer treatment. The company was pre-commercial at the time of acquisition, focusing on developing PNT2002 and PNT2003 through clinical trials.
Marketing channels2 records
Point Biopharma product offering
Product offeringCore offering
Point Biopharma developed next-generation radioligand therapies (RLTs) that use Lutetium-177 radioactive isotopes conjugated to tumor-targeting ligands to selectively deliver cytotoxic radiation to cancer cells. Its lead clinical candidates were PNT2002, a PSMA-targeted therapy for metastatic castration-resistant prostate cancer, and PNT2003, a somatostatin receptor-positive therapy for gastroenteropancreatic neuroendocrine tumors. The company operated radiopharmaceutical manufacturing in Indianapolis and R&D in Toronto.
Product overview
Point Biopharma Global Inc. was a radiopharmaceutical company focused on developing targeted radioligand therapies for cancer treatment. The company's portfolio included two lead product candidates: PNT2002 (Lu-177-PNT2002), a PSMA-targeted therapy for metastatic castration-resistant prostate cancer, and PNT2003, a radioequivalent to Lutathera for gastroenteropancreatic neuroendocrine tumors. Point Biopharma operated radiopharmaceutical manufacturing facilities in Indianapolis and an R&D center in Toronto. The company was acquired by Eli Lilly in December 2023 for approximately $1.4 billion to strengthen Lilly's radiopharmaceutical capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- PNT2002 (Lu-177-PNT2002)
Quantifiable outcome
- PNT2002 demonstrated positive topline results from Phase 3 SPLASH study for metastatic castration-resistant prostate cancer
- +1 more outcomes
Companies that use Point Biopharma
Customer profileSegments1 record
Ideal customer profiles2 records
Point Biopharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Point Biopharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Eli Lilly and CompanyflagshipEli Lilly acquired Point Biopharma Global Inc. for approximately $1.4 billion in December 2023, integrating Point Biopharma's radiopharmaceutical capabilities into Lilly's oncology strategy. The acquisition expanded Lilly's radioligand therapy pipeline with PNT2002 for prostate cancer and PNT2003 for neuroendocrine tumors. This was part of a broader wave of radiopharma acquisitions by major pharma companies, including BMS's $4.1B acquisition of RayzeBio and AstraZeneca's $2.4B acquisition of Fusion Pharmaceuticals.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
Point Biopharma competitors and assessment
Company assessmentDirect peers
- Novartis: Novartis commercializes Pluvicto (177Lu-PSMA-617), the first FDA-approved PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer — directly competing with Point's PNT2002 in the same indication and using the same Lutetium-177 isotope. Also markets Lutathera in neuroendocrine tumors, overlapping with PNT2003.
- Lantheus Holdings: Lantheus licensed exclusive worldwide rights to PNT2003 from Point Biopharma in December 2022 (deal worth up to $2B) and is a leading radiopharmaceutical-focused company with a portfolio spanning diagnostics and therapeutics in oncology — directly comparable as a radioligand player targeting the same GEP-NET and PSMA spaces.
- Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company developing and selling diagnostic and therapeutic agents in urologic oncology (PSMA imaging) and other oncology indications, overlapping with Point's PSMA-focused pipeline and Indianapolis-area operational footprint.
- Fusion Pharmaceuticals: Fusion developed targeted alpha therapies (actinium-225) for cancer and was acquired by AstraZeneca in 2024 for $2.4B — a near-perfect comparable in scale, therapeutic modality, and exit profile (radiopharma acquisition by big pharma) to Point Biopharma.
- RayzeBio: RayzeBio developed actinium-225-based radiopharmaceuticals for solid tumors and was acquired by Bristol-Myers Squibb in 2024 for $4.1B — another direct peer in therapeutic radiopharmaceuticals with an analogous big-pharma-acquisition exit and comparable modality overlap.
Broad incumbents
- Bayer: Bayer markets Xofigo (radium-223), an alpha-emitting radiopharmaceutical for metastatic castration-resistant prostate cancer, and is investing in radioligand platforms through its broader oncology franchise — a broad incumbent operating in Point's target indication with an overlapping mechanism category.
- Curium Pharma: Curium is one of the largest commercial radiopharmaceutical manufacturers globally, producing diagnostic and therapeutic nuclear medicine products across PET, SPECT, and therapeutic isotopes — a broad incumbent with manufacturing and distribution capabilities comparable to Point's Indianapolis facility.
- Bracco Imaging: Bracco Imaging is a major diagnostic imaging agent and radiopharmaceutical company with a broad portfolio of contrast media and nuclear medicine products — comparable as an established radiopharmaceutical incumbent with overlapping manufacturing and nuclear medicine distribution capabilities.
Emerging players
- ITM Isotope Technologies Munich: ITM is a specialized radiopharmaceutical company developing targeted therapeutic radioisotopes (notably Lutetium-177 and actinium-225) for oncology — overlapping with Point's isotope and manufacturing platform but with a distinct focus on isotope supply and emerging targeted radionuclide therapies.
Others
- ABX-CRO / PETNET Solutions: PETNET Solutions (a Siemens Healthineers company) operates a large commercial PET radiopharmacy manufacturing and distribution network in the US and Europe — comparable as a radiopharmacy production and distribution peer relevant to Point's Indianapolis manufacturing and future commercial supply chain.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Point Biopharma social profiles
Digital presencePoint Biopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Point Biopharma leadership team
Management profileNumber of profiles
Profiles6 records
Point Biopharma funding detail
Funding detailFunding overview
Funding rounds3 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Point Biopharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Point Biopharma
What does Point Biopharma do?
Point Biopharma developed next-generation radioligand therapies (RLTs) that use Lutetium-177 radioactive isotopes conjugated to tumor-targeting ligands to selectively deliver cytotoxic radiation to cancer cells. Its lead clinical candidates were PNT2002, a PSMA-targeted therapy for metastatic castration-resistant prostate cancer, and PNT2003, a somatostatin receptor-positive therapy for gastroenteropancreatic neuroendocrine tumors. The company operated radiopharmaceutical manufacturing in Indianapolis and R&D in Toronto.
Is Point Biopharma a public or private company?
Point Biopharma is a public company. It is classified as corporate owned and is currently acquired.
When was Point Biopharma founded?
Point Biopharma was founded in 2017. It employs 51 to 100 people.
Where is Point Biopharma based?
Point Biopharma is headquartered in Indianapolis, United States, in the North America region.
How does Point Biopharma make money?
One revenue line is on record: radiopharmaceutical Development.
Who are Point Biopharma's main competitors?
Direct peers on record are Novartis, Lantheus Holdings, Telix Pharmaceuticals, Fusion Pharmaceuticals and RayzeBio. Broad incumbents are Bayer, Curium Pharma and Bracco Imaging. ITM Isotope Technologies Munich is listed as an emerging player. ABX-CRO / PETNET Solutions is listed as an others.
Does Point Biopharma have an API?
No public API is recorded for Point Biopharma.
What industry is Point Biopharma in?
Point Biopharma's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 3254 and its SIC code is 2834.